John Ludes-Meyers
Overview
Explore the profile of John Ludes-Meyers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schaub J, Chou C, Kuo H, Javanmardi K, Hsieh C, Goldsmith J, et al.
Nat Protoc
. 2021 Oct;
16(11):5339-5356.
PMID: 34611365
The severe acute respiratory syndrome coronavirus 2 spike protein is a critical component of coronavirus disease 2019 vaccines and diagnostics and is also a therapeutic target. However, the spike protein...
2.
Hsieh C, Goldsmith J, Schaub J, DiVenere A, Kuo H, Javanmardi K, et al.
Science
. 2020 Jul;
369(6510):1501-1505.
PMID: 32703906
The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein, which is metastable...
3.
Hsieh C, Goldsmith J, Schaub J, DiVenere A, Kuo H, Javanmardi K, et al.
bioRxiv
. 2020 Jun;
PMID: 32577660
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has led to accelerated efforts to develop therapeutics, diagnostics, and vaccines to mitigate this public health emergency. A key target of...
4.
Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose J, et al.
Eur J Cancer
. 2016 Dec;
70:156.
PMID: 27919550
No abstract available.
5.
Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose J, et al.
Eur J Cancer
. 2016 May;
61:20-8.
PMID: 27136102
Alofanib (RPT835) is a novel selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). We showed previously that alofanib could bind to the extracellular domain of FGFR2 and has...
6.
Tsimafeyeu I, Daeyaert F, Joos J, Aken K, Ludes-Meyers J, Byakhov M, et al.
Med Chem
. 2016 Jan;
12(4):303-17.
PMID: 26732115
Background: Fibroblast growth factor (FGF) receptors (FGFRs) play a key role in tumor growth and angiogenesis. The present report describes our search for an extracellularly binding FGFR inhibitor using a...
7.
Nunez M, Ludes-Meyers J, Aldaz C
J Mol Histol
. 2006 Aug;
37(3-4):115-25.
PMID: 16941225
WWOX is a putative tumor suppressor gene that spans approximately a 1 Mb genomic region and is the site for the second most common chromosomal fragile site, FRA16D at 16q23....
8.
Nunez M, Ludes-Meyers J, Abba M, Kil H, Abbey N, Page R, et al.
Breast Cancer Res Treat
. 2005 Feb;
89(2):99-105.
PMID: 15692750
WWOX is a cancer gene, spanning the common chromosomal fragile site 16D. Genomic and expression aberrations affecting this gene and locus are common in various neoplasias including breast cancer. The...
9.
Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim H, Lu C, et al.
Oncogene
. 2002 Oct;
21(50):7680-9.
PMID: 12400010
AP-1 transcription factors play a critical role in signal transduction pathways in many cells. We have investigated the role of AP-1 in controlling proliferative signals in breast cells, and have...